JP2015500792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500792A5 JP2015500792A5 JP2014526308A JP2014526308A JP2015500792A5 JP 2015500792 A5 JP2015500792 A5 JP 2015500792A5 JP 2014526308 A JP2014526308 A JP 2014526308A JP 2014526308 A JP2014526308 A JP 2014526308A JP 2015500792 A5 JP2015500792 A5 JP 2015500792A5
- Authority
- JP
- Japan
- Prior art keywords
- clostridium
- bacterium
- lachnospiraceae bacterium
- composition according
- homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565976P | 2011-12-01 | 2011-12-01 | |
| US61/565,976 | 2011-12-01 | ||
| US201261607360P | 2012-03-06 | 2012-03-06 | |
| US61/607,360 | 2012-03-06 | ||
| PCT/JP2012/007687 WO2013080561A1 (en) | 2011-12-01 | 2012-11-29 | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017213526A Division JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500792A JP2015500792A (ja) | 2015-01-08 |
| JP2015500792A5 true JP2015500792A5 (https=) | 2016-06-16 |
| JP6306507B2 JP6306507B2 (ja) | 2018-04-18 |
Family
ID=48535050
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526308A Active JP6306507B2 (ja) | 2011-12-01 | 2012-11-29 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2017213526A Active JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2019038453A Active JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2021005834A Active JP7165218B2 (ja) | 2011-12-01 | 2021-01-18 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2022168855A Active JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2024087782A Pending JP2024129016A (ja) | 2011-12-01 | 2024-05-30 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017213526A Active JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2019038453A Active JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2021005834A Active JP7165218B2 (ja) | 2011-12-01 | 2021-01-18 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2022168855A Active JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2024087782A Pending JP2024129016A (ja) | 2011-12-01 | 2024-05-30 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Country Status (10)
| Country | Link |
|---|---|
| US (11) | US10238694B2 (https=) |
| EP (4) | EP3569690B1 (https=) |
| JP (6) | JP6306507B2 (https=) |
| CN (3) | CN116942833A (https=) |
| CA (1) | CA2892588A1 (https=) |
| DK (2) | DK3978598T3 (https=) |
| ES (2) | ES2993669T3 (https=) |
| FI (2) | FI3569690T3 (https=) |
| HK (1) | HK1204008A1 (https=) |
| WO (1) | WO2013080561A1 (https=) |
Families Citing this family (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| PH12013500224A1 (en) | 2010-08-04 | 2013-04-08 | Borody Thomas J | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| JP5931884B2 (ja) | 2010-10-07 | 2016-06-08 | カリフォルニア インスティチュート オブ テクノロジー | 自閉症の生菌療法 |
| MX2013010343A (es) | 2011-03-09 | 2014-04-30 | Univ Minnesota | Composicion y metodos para el transplante de microbiota de colon. |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN116942833A (zh) | 2011-12-01 | 2023-10-27 | 国立大学法人 东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
| IN2014DN07752A (https=) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| JP6203816B2 (ja) | 2012-03-29 | 2017-09-27 | セラバイオーム，エルエルシー | 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤 |
| WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| WO2014036182A2 (en) | 2012-08-29 | 2014-03-06 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| CA3212215A1 (en) | 2012-11-23 | 2014-05-30 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| HK1218560A1 (zh) | 2013-02-04 | 2017-02-24 | Seres Therapeutics, Inc. | 组成与方法 |
| CA2899925A1 (en) | 2013-02-04 | 2014-08-07 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| EP2967077A4 (en) | 2013-03-15 | 2016-09-14 | Seres Therapeutics Inc | NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| EP3074027B1 (en) | 2013-11-25 | 2024-12-18 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| JP6617935B2 (ja) * | 2014-04-10 | 2019-12-11 | 国立研究開発法人理化学研究所 | Ｔｈ１７細胞の誘導のための組成物及び方法 |
| US20150322176A1 (en) * | 2014-04-16 | 2015-11-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof |
| PT3146065T (pt) * | 2014-05-19 | 2025-01-14 | Memorial Sloan Kettering Cancer Center | Métodos e composições para reduzir a infecção por clostridium difficile |
| WO2016069801A1 (en) | 2014-10-30 | 2016-05-06 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders |
| EA201790811A1 (ru) | 2014-10-30 | 2017-11-30 | Калифорния Инститьют Оф Текнолоджи | Содержащие бактерии композиции и способы для улучшения видов поведения при нарушениях неврологического развития |
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| CA3254897A1 (en) * | 2014-11-25 | 2026-03-02 | Memorial Sloan-Kettering Cancer Center | Intestinal microbiota and gvhd |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| WO2016102950A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Immune modulation |
| SG11201704814SA (en) | 2014-12-23 | 2017-07-28 | 4D Pharma Res Ltd | Pirin polypeptide and immune modulation |
| US20170360853A1 (en) * | 2015-01-07 | 2017-12-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Gastro-Intestinal Biomarkers for Diagnosis and Therapies of Proteinopathies |
| CA2985827A1 (en) | 2015-05-14 | 2016-11-17 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| AU2016268158B2 (en) | 2015-05-22 | 2022-03-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| HRP20191949T1 (hr) * | 2015-06-15 | 2020-01-24 | 4D Pharma Research Limited | Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| ME03511B (me) | 2015-06-15 | 2020-04-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2016209806A1 (en) * | 2015-06-22 | 2016-12-29 | President And Fellows Of Harvard College | Induction of lamina propria regulatory t cells |
| US10851399B2 (en) | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| US9938558B2 (en) | 2015-06-25 | 2018-04-10 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| MX388995B (es) | 2015-06-25 | 2025-03-20 | Native Microbials Inc | Métodos, aparatos y sistemas para analizar cepas de microorganismos de comunidades heterogéneas complejas, predecir e indentificar sus relaciones funcionales e interacciones y seleccionar y sintetizar conjuntos microbianos basados en estos. |
| WO2017120495A1 (en) | 2016-01-07 | 2017-07-13 | Ascus Biosciences, Inc. | Methods for improving milk production by administration of microbial consortia |
| CA3006057A1 (en) * | 2015-09-09 | 2017-03-16 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues |
| CN115252650A (zh) | 2015-11-03 | 2022-11-01 | 布里格姆及妇女医院股份有限公司 | 用于治疗和/或预防食物变态反应的治疗性微生物群 |
| HK1254843B (zh) | 2015-11-20 | 2020-04-17 | 希杰生物科技株式会社 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US20190247447A1 (en) * | 2015-11-24 | 2019-08-15 | Seres Therapeutics, Inc. | Designed bacterial compositions |
| JP6675752B2 (ja) * | 2016-02-23 | 2020-04-01 | 国立大学法人佐賀大学 | 腸内Ｂｌａｕｔｉａ ｃｏｃｃｏｉｄｅｓ増殖刺激剤 |
| SG10201913557TA (en) | 2016-03-04 | 2020-02-27 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2017160711A1 (en) | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US11260083B2 (en) | 2016-03-15 | 2022-03-01 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| EP3850953B1 (en) | 2016-06-10 | 2023-11-01 | N.V. Nutricia | Nutrition to reduce the risk of allergy |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| JP7168558B2 (ja) * | 2016-06-14 | 2022-11-09 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10722600B2 (en) | 2016-06-17 | 2020-07-28 | New York University | Methods and compositions for treating cancer |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US20180185421A1 (en) * | 2016-08-29 | 2018-07-05 | Tokyo Metropolitan Government | Composition comprising fecal microbiota |
| JP7542946B2 (ja) | 2016-09-27 | 2024-09-02 | ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11447738B2 (en) * | 2016-10-28 | 2022-09-20 | Vedanta Biosciences, Inc. | Methods and compositions for preserving bacteria |
| JP7482494B2 (ja) * | 2016-11-01 | 2024-05-14 | 慶應義塾 | Ｔｈ１細胞を誘導する細菌 |
| US11571446B2 (en) * | 2016-11-18 | 2023-02-07 | Sanford Bumham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018107365A1 (zh) * | 2016-12-13 | 2018-06-21 | 深圳华大基因研究院 | 粪厌氧棒杆菌(Anaerostipes caccae)及其应用 |
| US11167018B2 (en) * | 2016-12-23 | 2021-11-09 | Keio University | Compositions and methods for the induction of CD8+ T-cells |
| CN110366596A (zh) | 2016-12-28 | 2019-10-22 | 埃斯库斯生物科技股份公司 | 用于对复杂异质群落中的完整微生物株系进行分析、确定其功能关系及相互作用以及基于此来识别和合成生物活性改性剂的方法、设备和系统 |
| JP2020503048A (ja) | 2016-12-28 | 2020-01-30 | アスカス バイオサイエンシーズ， インコーポレイテッド | トレーサー分析論による複雑な不均一コミュニティの微生物株の解析、その機能的関連性及び相互作用の決定、ならびに微生物アンサンブル（投与される微生物アンサンブル及び接種される微生物アンサンブルを含む）の合成、のための方法、装置、及びシステム |
| US20200023018A1 (en) * | 2017-02-07 | 2020-01-23 | California Institute Of Technology | Modulation of gut microbiota in huntington's disease and rett syndrome |
| US10596206B1 (en) | 2017-03-14 | 2020-03-24 | Cornell University | Probiotic compositions and methods of use |
| CA3211208A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| CN110831606A (zh) | 2017-04-05 | 2020-02-21 | 克雷斯顿沃控股公司 | 治疗帕金森氏病(pd)和相关疾病的组合物和方法 |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| US11044924B2 (en) | 2017-04-28 | 2021-06-29 | Native Microbials, Inc. | Methods for supporting grain intensive and or energy intensive diets in ruminants by administration of a synthetic bioensemble of microbes or purified strains therefor |
| EP3624818A4 (en) | 2017-05-19 | 2021-04-14 | Memorial Sloan-Kettering Cancer Center | METHODS AND COMPOSITIONS FOR REDUCING INFECTION OR COLONIZATION WITH LISTERIA MONOCYTOGENES |
| ES2877726T3 (es) | 2017-05-22 | 2021-11-17 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| JP2020521760A (ja) | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法 |
| TWI812624B (zh) | 2017-06-14 | 2023-08-21 | 南韓商希杰生物科技股份有限公司 | 包含細菌品系之組成物 |
| PL3600363T3 (pl) | 2017-06-14 | 2021-06-14 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| ES2841902T3 (es) | 2017-06-14 | 2021-07-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| GB201709763D0 (en) * | 2017-06-19 | 2017-08-02 | Probi Ab | Biological materials and methods |
| US20200376044A1 (en) * | 2017-08-04 | 2020-12-03 | Tarunmeet GUJRAL | Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics |
| WO2019032573A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER |
| JP2020530493A (ja) * | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 腸内の抗生物質耐性菌を除菌するための組成物及び方法 |
| EP3668527A1 (en) | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| JP2021501185A (ja) | 2017-10-30 | 2021-01-14 | セレス セラピューティクス インコーポレイテッド | 抗生物質耐性を処置するための組成物及び方法 |
| EP3476396A1 (en) * | 2017-10-31 | 2019-05-01 | Institut Gustave Roussy | Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same |
| AU2018365071B2 (en) * | 2017-11-09 | 2025-09-11 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| US10507221B2 (en) | 2017-11-09 | 2019-12-17 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| US12053495B2 (en) | 2017-12-11 | 2024-08-06 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| US20200368293A1 (en) * | 2018-01-18 | 2020-11-26 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
| WO2019156234A1 (en) | 2018-02-09 | 2019-08-15 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
| EP3594321A1 (en) * | 2018-07-10 | 2020-01-15 | Université catholique de Louvain | Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| DE102018213030A1 (de) * | 2018-08-03 | 2020-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien |
| WO2020037271A1 (en) | 2018-08-17 | 2020-02-20 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
| JP7444459B2 (ja) * | 2018-10-04 | 2024-03-06 | 国立研究開発法人理化学研究所 | ＩＬＣ２を標的としたＩｇＡ産生誘導方法 |
| CN113271796A (zh) * | 2018-11-05 | 2021-08-17 | 芝加哥大学 | 用于治疗感染性、自身免疫和过敏性疾病的方法和组合物 |
| WO2020106983A1 (en) | 2018-11-21 | 2020-05-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer |
| WO2020234746A1 (en) | 2019-05-18 | 2020-11-26 | Janssen Biotech, Inc. | Materials and methods for microbiome modulation |
| CN114258299A (zh) * | 2019-07-17 | 2022-03-29 | 犹他大学研究基金会 | 梭菌纲聚生体组合物以及治疗肥胖症、代谢综合征和肠易激疾病的方法 |
| US12290538B2 (en) | 2019-07-19 | 2025-05-06 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders |
| JP2022544369A (ja) * | 2019-08-14 | 2022-10-18 | ヴァーヘニンゲン・ウニヴェルシテイト | ミオ－イノシトール－プロピオネート経路を含む細菌 |
| EP4013850A1 (en) | 2019-08-16 | 2022-06-22 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| US20250270498A1 (en) * | 2019-08-16 | 2025-08-28 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| EP4013851A1 (en) | 2019-08-16 | 2022-06-22 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| JP2021045097A (ja) * | 2019-09-20 | 2021-03-25 | 腸内フローラ移植臨床研究株式会社 | 腸内フローラの健康状態の診断方法及びその利用 |
| CN115243697A (zh) * | 2019-11-22 | 2022-10-25 | 未知君有限责任公司 | 包含细菌物种的组合物及其相关方法 |
| EP4125969A1 (en) * | 2020-03-25 | 2023-02-08 | Institut National de la Santé et de la Recherche Médicale (INSERM) | New strategy to treat and prevent diseases caused by enterobacteriae |
| EP3895710A1 (en) | 2020-04-15 | 2021-10-20 | DSM IP Assets B.V. | Food and/or feed compositions to manage immune homeostasis |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| BR112022023687A2 (pt) * | 2020-05-21 | 2022-12-20 | Superbrewed Food Inc | Método de tratar ou prevenir uma infecção |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| US12011467B2 (en) | 2021-05-18 | 2024-06-18 | J. Craig Venter Institute, Inc. | Bacterial formulation |
| CN116195742B (zh) * | 2021-11-30 | 2024-07-09 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99在保护软骨中的应用 |
| EP4442280A4 (en) * | 2021-12-02 | 2025-11-19 | Kanagawa Institute Of Industrial Science And Tech | IMPLEMENTATION OF THERAPY AND DIAGNOSIS FOR ALLERGIC DISEASES THROUGH THE REGULATION OF IMMUNOGLOBULIN-BINDING PROTEIN |
| CN114917252A (zh) * | 2021-12-29 | 2022-08-19 | 慕恩（广州）生物科技有限公司 | 毛螺菌科微生物菌株、预防和/或治疗肿瘤的药物及应用 |
| CN119970806B (zh) * | 2025-02-25 | 2026-03-03 | 浙江大学 | 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3068965D1 (en) | 1979-11-16 | 1984-09-20 | Sterosynt Ltd | 6-alpha-fluoro-16-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US5700787A (en) | 1994-09-02 | 1997-12-23 | Brigham & Women's Hospital, Inc. | Capsular polysaccharide immunomodulator |
| DE69635496T2 (de) | 1995-09-15 | 2006-07-27 | Gerding, Dale N., Chicago | Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| DE69738975D1 (de) | 1996-03-20 | 2008-10-23 | Univ New South Wales Kensingto | Veränderung der mikrobenflora im verdauungstrakt |
| US5922352A (en) | 1997-01-31 | 1999-07-13 | Andrx Pharmaceuticals, Inc. | Once daily calcium channel blocker tablet having a delayed release core |
| US6551632B2 (en) | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| JP2001112485A (ja) | 1999-10-19 | 2001-04-24 | Yakult Honsha Co Ltd | 腸内細菌用プライマー及び該プライマーを用いた検出方法 |
| FR2808689B1 (fr) | 2000-05-11 | 2004-09-03 | Agronomique Inst Nat Rech | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| SV2003000753A (es) | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
| WO2002080963A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| PE20030283A1 (es) | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| GB0220809D0 (en) * | 2002-09-06 | 2002-10-16 | Univ College Of London | Immune modulator |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| CA2520865A1 (en) | 2003-03-31 | 2004-10-21 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
| WO2004104175A2 (en) | 2003-05-14 | 2004-12-02 | University Of Georgia Research Foundation, Inc. | Probiotic bacteria and methods |
| JP2005124495A (ja) | 2003-10-24 | 2005-05-19 | Yakult Honsha Co Ltd | ヒト腸内細菌検出用プライマー |
| JPWO2005094886A1 (ja) | 2004-03-31 | 2008-02-14 | キリンファーマ株式会社 | Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物 |
| US8092793B2 (en) | 2004-12-15 | 2012-01-10 | Qingdao East Sea Pharmaceuticals, Ltd. | Treating inflammatory bowel disease with live bacteria |
| KR101312745B1 (ko) | 2005-03-03 | 2013-09-27 | 가부시키가이샤 메이지 | 면역기능 조정제 |
| CU23581A1 (es) * | 2005-10-28 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer |
| WO2007092451A2 (en) | 2006-02-06 | 2007-08-16 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
| DE102006062250A1 (de) | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
| ES2399993T3 (es) | 2007-03-02 | 2013-04-04 | Protectimmun Gmbh | Composición farmacéutica para la protección frente a alergias y enfermedades inflamatorias |
| EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
| CN101310730A (zh) | 2007-05-27 | 2008-11-26 | 青岛东海药业有限公司 | 酪酸梭菌在制备防治类风湿性关节炎、强直性脊柱炎微生物制剂中的应用 |
| JP2009084215A (ja) | 2007-09-28 | 2009-04-23 | Nippon Paper Chemicals Co Ltd | 炎症性腸疾患予防・治療剤 |
| WO2009050486A2 (en) | 2007-10-19 | 2009-04-23 | The University Of Surrey | Peptide manipulators of regulatory t cell activity |
| EP2217250A4 (en) | 2007-11-09 | 2011-01-05 | California Inst Of Techn | IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS |
| CN101496819A (zh) | 2008-01-31 | 2009-08-05 | 青岛东海药业有限公司 | 真杆菌、梭菌制剂及其应用 |
| KR100913405B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물 |
| WO2009149149A1 (en) | 2008-06-04 | 2009-12-10 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
| JP2010129134A (ja) | 2008-11-28 | 2010-06-10 | Pulstec Industrial Co Ltd | ホログラム記録装置及びホログラム再生装置 |
| ES2799891T3 (es) | 2009-02-13 | 2020-12-22 | Univ California | Dispositivo, composición y método para el diagnóstico basado en tejidos |
| GB0903016D0 (en) | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| CA2754604A1 (en) | 2009-03-13 | 2010-09-16 | Da Volterra | Compositions and methods for elimination of gram-negative bacteria |
| JP2012524910A (ja) | 2009-04-23 | 2012-10-18 | カリフォルニア インスティチュート オブ テクノロジー | 免疫調節物質の同定方法及びシステム |
| US20100311686A1 (en) | 2009-06-03 | 2010-12-09 | Kasper Lloyd H | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
| WO2011022542A2 (en) | 2009-08-19 | 2011-02-24 | Puretech Ventures, Llc | Administration of factors normally present in a microbial niche to improve health |
| WO2011022660A1 (en) | 2009-08-21 | 2011-02-24 | Puretech Ventures, Llc | Methods of diagnosing and treating microbiome-associated disease using interaction network parameters |
| WO2011027956A2 (ko) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
| US20120276149A1 (en) * | 2009-10-15 | 2012-11-01 | Dan Littman | Methods for modulating bacterial infection |
| ES2610829T3 (es) | 2009-11-11 | 2017-05-03 | Alimentary Health Limited | Cepa de Bifidobacterium |
| US20120301450A1 (en) * | 2010-02-10 | 2012-11-29 | Hirokuni Miyamoto | Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism |
| WO2011151941A1 (ja) * | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| US20120020941A1 (en) | 2010-07-26 | 2012-01-26 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| WO2012013861A2 (en) | 2010-07-26 | 2012-02-02 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| ES2388662B1 (es) | 2010-11-10 | 2014-04-11 | Consejo Superior De Investigaciones Científicas (Csic) | Nuevas cepas de duganella aisladas de la rizosfera de olivo silvestre y cultivado y su uso en la producción de violaceína. |
| US20120279149A1 (en) * | 2011-05-04 | 2012-11-08 | Sebastian George Quinn | System and device for utilization of energy in buildings |
| US20140171339A1 (en) * | 2011-06-06 | 2014-06-19 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof |
| ES2662793T3 (es) | 2011-09-14 | 2018-04-09 | Nubiyota Llc | Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN116942833A (zh) * | 2011-12-01 | 2023-10-27 | 国立大学法人 东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| CA2896795A1 (en) | 2012-11-26 | 2014-05-30 | Thomas Julius Borody | Compositions for the restoration of a fecal microbiota and methods for making and using them |
| CA2899925A1 (en) | 2013-02-04 | 2014-08-07 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
| US20160040215A1 (en) | 2013-03-14 | 2016-02-11 | Seres Therapeutics, Inc. | Methods for Pathogen Detection and Enrichment from Materials and Compositions |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| EP2967077A4 (en) | 2013-03-15 | 2016-09-14 | Seres Therapeutics Inc | NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD |
| WO2015006355A2 (en) * | 2013-07-09 | 2015-01-15 | Puretech Ventures, Llc | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| JP6617935B2 (ja) | 2014-04-10 | 2019-12-11 | 国立研究開発法人理化学研究所 | Ｔｈ１７細胞の誘導のための組成物及び方法 |
| WO2015198105A1 (en) | 2014-06-27 | 2015-12-30 | Telefonaktiebolaget L M Ericsson (Publ) | System and method for supporting time-sensitive services in a communication network |
| MX381919B (es) | 2014-06-30 | 2025-03-13 | Salix Pharmaceuticals Inc | Métodos para repetir tratamiento de síndrome del intestino irritable (ibs). |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| WO2016194427A1 (ja) | 2015-05-30 | 2016-12-08 | 日環科学株式会社 | プロバイオティクス、あるいはプレバイオティクス、並びにその製造方法、微生物製剤、健康食品並びに医薬品 |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US9642281B1 (en) * | 2015-12-28 | 2017-05-02 | Martas Precision Slide Co., Ltd. | Buckle set for sliding rail of industrial rackmount chassis |
| WO2017160711A1 (en) * | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US11260083B2 (en) | 2016-03-15 | 2022-03-01 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| US20170290889A1 (en) | 2016-04-11 | 2017-10-12 | New York University | Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders |
| JP6792103B2 (ja) | 2016-06-01 | 2020-11-25 | 株式会社テックコーポレーション | 微細気泡水供給システム |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| JP7482494B2 (ja) | 2016-11-01 | 2024-05-14 | 慶應義塾 | Ｔｈ１細胞を誘導する細菌 |
| US11167018B2 (en) * | 2016-12-23 | 2021-11-09 | Keio University | Compositions and methods for the induction of CD8+ T-cells |
| JP2020530493A (ja) | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 腸内の抗生物質耐性菌を除菌するための組成物及び方法 |
| JP2019046634A (ja) * | 2017-08-31 | 2019-03-22 | パナソニックＩｐマネジメント株式会社 | 照明システム及びコントローラ |
| US10507221B2 (en) * | 2017-11-09 | 2019-12-17 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| US12053495B2 (en) | 2017-12-11 | 2024-08-06 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| WO2019156234A1 (en) | 2018-02-09 | 2019-08-15 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
| WO2020037271A1 (en) | 2018-08-17 | 2020-02-20 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| WO2020234746A1 (en) | 2019-05-18 | 2020-11-26 | Janssen Biotech, Inc. | Materials and methods for microbiome modulation |
| US20240173365A1 (en) | 2021-06-28 | 2024-05-30 | Vedanta Biosciences, Inc. | Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease |
-
2012
- 2012-11-29 CN CN202310526067.8A patent/CN116942833A/zh active Pending
- 2012-11-29 EP EP19178787.8A patent/EP3569690B1/en active Active
- 2012-11-29 HK HK15104633.8A patent/HK1204008A1/xx unknown
- 2012-11-29 CA CA2892588A patent/CA2892588A1/en active Pending
- 2012-11-29 ES ES21198256T patent/ES2993669T3/es active Active
- 2012-11-29 US US14/362,097 patent/US10238694B2/en active Active
- 2012-11-29 WO PCT/JP2012/007687 patent/WO2013080561A1/en not_active Ceased
- 2012-11-29 FI FIEP19178787.8T patent/FI3569690T3/fi active
- 2012-11-29 EP EP24196410.5A patent/EP4477750A3/en active Pending
- 2012-11-29 ES ES19178787T patent/ES2994320T3/es active Active
- 2012-11-29 EP EP12854485.5A patent/EP2785828B1/en active Active
- 2012-11-29 CN CN201810228890.XA patent/CN108676774B/zh active Active
- 2012-11-29 EP EP21198256.6A patent/EP3978598B1/en active Active
- 2012-11-29 FI FIEP21198256.6T patent/FI3978598T3/fi active
- 2012-11-29 CN CN201280068081.8A patent/CN104160014A/zh active Pending
- 2012-11-29 DK DK21198256.6T patent/DK3978598T3/da active
- 2012-11-29 DK DK19178787.8T patent/DK3569690T3/da active
- 2012-11-29 JP JP2014526308A patent/JP6306507B2/ja active Active
-
2016
- 2016-02-09 US US15/019,068 patent/US9642881B2/en active Active
- 2016-02-09 US US15/019,101 patent/US9649345B2/en active Active
-
2017
- 2017-03-28 US US15/471,493 patent/US10052353B2/en active Active
- 2017-04-14 US US15/487,553 patent/US10058578B2/en active Active
- 2017-11-06 JP JP2017213526A patent/JP6492151B2/ja active Active
-
2018
- 2018-04-27 US US15/964,285 patent/US10183045B2/en active Active
- 2018-10-15 US US16/160,004 patent/US10342832B2/en active Active
- 2018-10-25 US US16/170,344 patent/US10835559B2/en active Active
-
2019
- 2019-03-04 JP JP2019038453A patent/JP7097838B2/ja active Active
- 2019-05-31 US US16/427,899 patent/US10624933B2/en active Active
-
2020
- 2020-10-15 US US17/071,425 patent/US11547732B2/en active Active
-
2021
- 2021-01-18 JP JP2021005834A patent/JP7165218B2/ja active Active
-
2022
- 2022-10-21 JP JP2022168855A patent/JP7503273B2/ja active Active
- 2022-12-20 US US18/068,725 patent/US12502411B2/en active Active
-
2024
- 2024-05-30 JP JP2024087782A patent/JP2024129016A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500792A5 (https=) | ||
| Demopoulos et al. | Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials | |
| US20250367242A1 (en) | Designed bacterial compositions and uses thereof | |
| JP2018039833A5 (https=) | ||
| Loretelli et al. | PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune response | |
| FI3978598T3 (fi) | Ihmisperäisiä bakteereja, jotka indusoivat regulatoristen t-solujen proliferaatiota tai kertymistä | |
| Boutin et al. | Bacterial–fungal interactions in the neonatal gut influence asthma outcomes later in life | |
| JP2021078504A5 (https=) | ||
| US12427175B2 (en) | Fecal fungome and therapeutic efficacy of fecal microbiota transplantation | |
| Patel et al. | Is prevention the best treatment? CMV after lung transplantation | |
| US20230125810A1 (en) | Designed bacterial compositions and uses thereof | |
| Liu et al. | Genetic variation of human respiratory syncytial virus among children with fever and respiratory symptoms in Shanghai, China, from 2009 to 2012 | |
| RU2019126797A (ru) | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора | |
| Rittà et al. | Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection | |
| Lehto et al. | Human herpesvirus-6 and-7 after lung and heart–lung transplantation | |
| Yamani et al. | The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study | |
| JP2016065039A5 (https=) | ||
| Durante-Mangoni et al. | Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: a single centre, prospective cohort study | |
| Galarraga et al. | Influence of ganciclovir prophylaxis on citomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients | |
| Bruminhent et al. | Impact of cytomegalovirus serostatus on allograft loss and mortality within the first year after kidney transplantation: an analysis of the national transplant registry | |
| Solidoro et al. | Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpesvirus infections | |
| Marco et al. | Retrospective study of pestivirus infection in Pyrenean chamois (Rupicapra pyrenaica) and other ungulates in the Pyrenees (NE Spain) | |
| Said et al. | Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients | |
| Goossens et al. | CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands | |
| Pavlakis et al. | BK virus infection after non-renal transplantation |